Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 18/20 | 0.71 |
| ▸ | CDK9 | P50750 | 16/20 | 0.71 |
| ▸ | CCNH | P51946 | 16/20 | 0.71 |
| ▸ | CCNT1 | O60563 | 15/20 | 0.71 |
| ▸ | MNAT1 | P51948 | 13/20 | 0.71 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.66 |
| ▸ | CDK2 | P24941 | 9/20 | 0.66 |
| ▸ | CCNK | O75909 | 11/20 | 0.63 |
| ▸ | CDK12 | Q9NYV4 | 11/20 | 0.63 |
| ▸ | CDK13 | Q14004 | 9/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.58 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28349384 | 1.00 | CDK7 (0.71) | CDK7CDK9CCNHCCNT1MNAT1 | |
| SCHEMBL18072817 | 0.89 | CDK7 (0.83) | CDK7CDK9CCNHCCNT1MNAT1 | |
| SCHEMBL23336344 | 0.88 | CDK7 (0.56) | CDK7CDK9CCNHCCNT1MNAT1 | |
| SCHEMBL16665147 | 0.86 | CDK7 (0.67) | CDK7CDK9CCNHCCNT1MNAT1 | |
| SCHEMBL23040294 | 0.86 | CDK7 (0.67) | CDK7CDK9CCNHCCNT1MNAT1 | |
| SCHEMBL18047268 | 0.85 | CDK7 (0.80) | CDK7CDK9CCNHCCNT1MNAT1 | |
| SCHEMBL24591549 | 0.83 | CDK7 (1.00) | CDK7CDK9CCNHCCNT1MNAT1 | |
| SCHEMBL20209243 | 0.83 | CDK7 (1.00) | CDK7CDK9CCNHCCNT1MNAT1 | |
| SCHEMBL19040186 | 0.83 | CDK7 (0.78) | CDK7CDK9CCNHCCNT1MNAT1 | |
| SCHEMBL17150659 | 0.83 | CDK7 (0.73) | CDK7CDK9CCNHCCNT1MNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3057956-B1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200197392-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| CN-105849099-B | Polycyclic inhibitors of cyclin dependent kinase 7(CDK7) | 达纳-法伯癌症研究所股份有限公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2019035866-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | PARAZA PHARMA, INC. (CA) | 2019-01-31 | — | — | US | disclosed |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | PARAZA PHARMA, INC. (CA) | 2019-01-31 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
| WO-2015058140-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK13, CDK3, CDK12 | CDK7 4/4885CDK9 16/4885CCNH 42/4885 |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | CDK7 4/4885CDK9 16/4885CCNH 42/4885 |
| US-20200197392-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX | CDK7, CDK17, MTOR | CDK7 1/4885CDK9 11/4885CCNH 16/4885 |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | CDK7 4/4885CDK9 16/4885CCNH 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.